NCT01480778已完成3 期
Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint will be the changes in FSH and LH secretion induced by daily administration of the drug for 21 consecutive days during the 28 days of participation in the trial.
研究概览
简要总结
Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations
详细描述
secondary objective
- Evaluation of the safety aspects of medicines such as type, frequency and intensity of adverse events between groups during the 28 day trial.
exploratory objective
- Evaluation of the pharmacokinetics of the drug administered through the dosage of serum hormone levonorgestrel and ethinyl estradiol for 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Comply with all study procedures, sign, initial and date back, of their own free will, the IC;
- •Women aged between 18 and 35 years, regardless of race and class;
- •Make use of safe non-hormonal method of contraception such as tubal ligation, non-hormonal IUDs or condoms, or be hysterectomised or be vasectomized sexual partner;
- •Examination of Beta-HCG negative;
- •with regular menstrual cycles every 24 to 32 days, at least the last three months;
- •present normal Pap test (current or during the past 02 years);
- •Present or vaginal examination found that the changes do not interfere in the study;
- •present levels of FSH, LH, estradiol and TT for the normal menstrual cycle, as well as normal transvaginal sonographic reports.
排除标准
- •Provide a contraindication to the use of steroids;
- •Use regular or prediction of drugs that interfere with the metabolism of the investigational products, such as antibiotics, anticonvulsants, anticoagulants and hypoglycemic drugs;
- •smokers or have stopped smoking less than 12 months;
- •Toxic-dependent;
- •BMI <18 and> 25;
- •have made use of topical or systemic sex hormone for at least two months before the start of the study;
- •Background and personal or family history of thrombosis or bleeding disorders or vascular disorders or cardiovascular disease;
- •Laboratory tests, gynecological ultrasound or changed, the medical criteria;
- •Individuals with allergies or rheumatic diseases for which is indicated the use of cortico-steroid medication;
- •carry any endocrine changes, especially pituitary and gonadal and / or who are advised to use hormones;
- •with lesions or abnormalities suspected or confirmed in the gonads.
- •personal or family history of breast cancer or other hormone-dependent breast pathology;
- •with hypertension or diabetes mellitus (for drug interactions between the COC and hypoglycemic agents and antihypertensives);
- •a) History of nausea with oral use of COCs; p) Any condition that may interfere with the discretion of the investigator in the study data as well as being the measurement of the study be deleterious to the patient.
研究组 & 干预措施
LNG+EE2
Experimental
pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
干预措施: LNG+EE2 (Drug)
Nordette
Active Comparator
pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
干预措施: Nordette (Drug)
结局指标
主要结局
The primary efficacy endpoint will be the changes in FSH and LH secretion induced by daily administration of the drug for 21 consecutive days during the 28 days of participation in the trial.
时间窗: 1, 2, 4, 7, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24 and 28 days
次要结局
- Safety of drugs: type, frequency and intensity of adverse events between groups during the 28 day trial. Exploratory investigation of the pharmacokinetics of the drug administered through the dosage of hormones in serum LNG and EE2 for 28 days.(PK: 1 (0, 1, 2, 3, 4, 5, 6, 12 e 18 hours after administration), 2, 7, 14, 21 and 28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control ParticipantsHepatic ImpairmentNCT05409911Shionogi25
已完成
1 期
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease SubjectsParkinson's DiseaseNCT00914602XenoPort, Inc.14
已完成
不适用
The formation of carbamazepine metabolites and carbamazepine-protein conjugates in epilepsy patientsISRCTN62125126niversity of Liverpool158
已完成
1 期
Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112PainNCT04375865Addpharma Inc.30
已完成
1 期
A Clinical Study to Evaluate PK, PD, and PG of Rosuvastatin in the ElderlyElderlyNCT03715101Seoul National University Hospital20